Post Profile

Bristol's Opdivo Disappoints in Lung Cancer, While Merck's Keytruda Surprises

FindTheCompany | Graphiq Shares of Bristol-Myers Squibb have fallen 26% since August, when a large study of lung cancer patients failed to demonstrate that its breakthrough cancer drug, Opdivo, could slow tumor growth or extend patients’ lives better than existing chemotherapies. The full results of that study are out this morning, presented [...]
read more


Related Posts

No silver lining in failed Bristol cancer drug trial

Health : Reuters: Health

COPENHAGEN (Reuters) - Bristol-Myers Squibb disappointed investors on Sunday as researchers detailed data for its Opdivo cancer immunotherapy, which was already known to have failed to do better than older chemotherapies in a closel...

Merck & Co., Inc. (MRK), Bristol Myers Squibb Co. (BMY): Breakthrough Melanoma Data Drives Pharmas Higher

Business & Finance / Investing : Insider Monkey

Yesterday, Merck & Co., Inc. (NYSE:MRK) reported overwhelmingly positive interim results for its experimental melanoma drug lambrolizumab. This antibody, which belongs to an emerging class of cancer therapeutics called PD-1 drugs, w...

Bristol Myers Squibb Getting Close To Lung Cancer Approval For Nivolumab

Business & Finance / Investing : Great Speculations

These developments are encouraging for Bristol-Myers Squibb, which earlier had fast tracked clinical trials of nivolumab due to successful results. Merck has already launched a similar drug this year and has first-mover advantage in...

Bristol lung-cancer setback puts rival Merck drug in driver seat

Health : Reuters: Health

(Reuters) - New data is likely to prompt doctors to abandon Bristol-Myers Squibb's immunotherapy Opdivo in favor of Merck & Co's rival Keytruda in a large segment of the lucrative lung cancer market, analysts said on Monday. The res...

Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo

Health : Reuters: Health

(Reuters) - Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges...


Copyright © 2016 Regator, LLC